Fenwick’s capital markets & public companies co-chair Rob Freedman spoke with GeekWire about the unprecedented surge of biotech IPOs in the state of Washington this year.
Freedman spoke with the publication about the strength of biotech and healthcare market, especially since the start of the pandemic. In the recent boom “investors are casting a wider net” beyond the concentrated biotech hubs of San Francisco and Boston, he said. “They recognize that there’s more out there.”
Freedman noted that as the Pacific Northwest biotech scene continues to grow, proven leadership will help to attract capital and marquee investors. “Good executives, good investors: I think it sort of snowballs,” he said—adding, “We’ll see how long it lasts.”
The full article is available on GeekWire.